Quick Answer
Caribou Biosciences, Inc. reported Stockholders Equity of $122.18 million for the year ending 2025.
- Caribou Biosciences, Inc. showed a decrease of -51.7% in Stockholders Equity from 2024 to 2025.
- This data is from Caribou Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.10 million | Q2 2020: -$3.67 million | Q3 2020: -$11.21 million | Q1 2021: -$35.69 million | Q2 2021: -$47.69 million | Q3 2021: $404.40 million | Q1 2022: $371.80 million | Q2 2022: $347.89 million | Q3 2022: $324.11 million | Q1 2023: $278.27 million | Q2 2023: $269.46 million | Q3 2023: $398.27 million | Q1 2024: $343.29 million | Q2 2024: $310.46 million | Q3 2024: $281.20 million | Q1 2025: $217.22 million | Q2 2025: $166.13 million | Q3 2025: $141.85 million.
- Over the full 8 years of available data (2018 to 2025), Caribou Biosciences, Inc.'s Stockholders Equity has grown by 308.0%.
- Historical annual values: Fiscal year 2025: $122.18 million | Fiscal year 2024: $252.95 million | Fiscal year 2023: $368.40 million | Fiscal year 2022: $300.87 million | Fiscal year 2021: $387.83 million | Fiscal year 2020: -$23.44 million | Fiscal year 2019: $7.46 million | Fiscal year 2018: $29.95 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: